QCi and INmune Bio partner to study XPro in Alzheimer’s
Both companies will analyse clinical and biomedical datasets to identify conditions that share the biological mechanisms targeted by XPro.
Drug Development
Charles River partners with Magellan Stem Cells on cell therapy
Pfizer partners with Enodia Therapeutics in $500m drug deal
China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
Southern Research secures NIH funding for drug testing hub
FDA approves Asahi Kasei’s Hovilpri for refractory HSV
Perceptive, Nucleus partner to support radiopharmaceutical development
Bio-Techne opens GMP small molecule facility in Bristol, UK
